Peroxisome-proliferator-activated receptors and cancers: complex stories (original) (raw)

• A unified nomenclature system for the nuclear receptor superfamily. Cell 97, 161–163 (1999).
• Kersten, S. & Wahli, W. Peroxisome proliferator activated receptor agonists. EXS 89, 141–151 (2000).
  CAS PubMed Google Scholar
• Tan, N. S. et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol. Cell. Biol. 22, 5114–5127 (2002). This paper addresses the question of the role of fatty-acid-binding proteins in the cytoplasmic transport and nuclear delivery of PPAR ligands, which are hydrophobic molecules, to their cognate nuclear receptor.
  Article CAS PubMed PubMed Central Google Scholar
• Surapureddi, S. et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor α-interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc. Natl Acad. Sci. USA 99, 11836–11841 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Mueller, E. et al. Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms. J. Biol. Chem. 277, 41925–41930 (2002).
  Article CAS PubMed Google Scholar
• Krogsdam, A. M. et al. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation. Biochem. J. 363, 157–165 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, Y., Hon, M. & Evans, R. M. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl Acad. Sci. USA 99, 2613–2618 (2002). This work indicates that PPARβ/δ interacts with co-repressors and competes with PPARα and PPARγ on PPAR response elements. PPARβ/δ could therefore act as a regulator of the expression of PPAR target genes, either through transcriptional activation or through competition with the two other PPAR isotypes and transcriptional repression.
  Article CAS PubMed PubMed Central Google Scholar
• Dowell, P. et al. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor α interacting protein. J. Biol. Chem. 274, 15901–15907 (1999).
  Article CAS PubMed Google Scholar
• Desvergne, B. & Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649–688 (1999).
  CAS PubMed Google Scholar
• Di-Poi, N., Tan, N. S., Michalik, L., Wahli, W. & Desvergne, B. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10, 721–733 (2002). First description of PPARβ/δ target genes, showing that PPARβ/δ controls the AKT1 survival pathway in keratinocytes. This paper presents a model for the anti-apoptotic role of PPARβ/δ.
  Article CAS PubMed Google Scholar
• Michalik, L. et al. PPAR expression and function during vertebrate development. Int. J. Dev. Biol. 46, 105–114 (2002).
  CAS PubMed Google Scholar
• Michalik, L., Desvergne, B. & Wahli W. Peroxisome proliferator-activated receptors β/δ: emerging roles for a previously neglected third family member. Curr. Opin. Lipidol. 14, 129–135 (2003).
  Article CAS PubMed Google Scholar
• Lock, E. A., Mitchell, A. M. & Elcombe, C. R. Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu. Rev. Pharmacol. Toxicol. 29, 145–163 (1989).
  Article CAS PubMed Google Scholar
• Vanden Heuvel, J. P. et al. Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,643. Toxicol. Appl. Pharmacol. 188, 185–198 (2003).
  Article CAS PubMed Google Scholar
• Corton, J. C., Lapinskas, P. J. & Gonzalez, F. J. Central role of PPARα in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat. Res. 448, 139–151 (2000).
  Article CAS PubMed Google Scholar
• Boitier, E., Gautier, J. C. & Roberts, R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp. Hepatol. 2, 3 (2003).
  Article PubMed PubMed Central Google Scholar
• Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650 (1990).
  Article CAS PubMed Google Scholar
• Lee, S. S. et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012–3022 (1995). This paper describes the phenotype of the Pparα -null mice, a clear demonstration that this receptor is the one mediating the effects of PP in rodent liver.
  Article CAS PubMed PubMed Central Google Scholar
• Peters, J. M., Cattley, R. C. & Gonzalez, F. J. Role of PPAR α in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18, 2029–2033 (1997).
  Article CAS PubMed Google Scholar
• Marsman, D. S., Cattley, R. C., Conway, J. G. & Popp, J. A. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res. 48, 6739–6744 (1988).
  CAS PubMed Google Scholar
• Isenberg, J. S., Kolaja, K. L., Ayoubi, S. A., Watkins, J. B. 3rd & Klaunig, J. E. Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. Carcinogenesis 18, 1511–1519 (1997).
  Article CAS PubMed Google Scholar
• Peters, J. M. et al. Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis 19, 1989–1994 (1998).
  Article CAS PubMed Google Scholar
• Bayly, A. C., Roberts, R. A. & Dive, C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J. Cell Biol. 125, 197–203 (1994).
  Article CAS PubMed Google Scholar
• Oberhammer, F. A. & Qin, H. M. Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-β 1. Carcinogenesis 16, 1363–1371 (1995).
  Article CAS PubMed Google Scholar
• Gill, J. H., James, N. H., Roberts, R. A. & Dive, C. The non-genotoxic hepatocarcinogen nafenopin suppresses rodent hepatocyte apoptosis induced by TGFβ1, DNA damage and Fas. Carcinogenesis 19, 299–304 (1998).
  Article CAS PubMed Google Scholar
• Gill, J. H., Brickell, P., Dive, C. & Roberts, R. A. The rodent non-genotoxic hepatocarcinogen nafenopin suppresses apoptosis preferentially in non-cycling hepatocytes but also elevates CDK4, a cell cycle progression factor. Carcinogenesis 19, 1743–1747 (1998).
  Article CAS PubMed Google Scholar
• Roberts, R. A. Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. Ann. NY Acad. Sci. 804, 588–611 (1996).
  Article CAS PubMed Google Scholar
• Roberts, R. A., James, N. H., Woodyatt, N. J., Macdonald, N. & Tugwood, J. D. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor α (PPAR α). Carcinogenesis 19, 43–48 (1998).
  Article CAS PubMed Google Scholar
• Reddy, J. K. & Rao, M. S. Oxidative DNA damage caused by persistent peroxisome proliferation: its role in hepatocarcinogenesis. Mutat. Res. 214, 63–68 (1989).
  Article CAS PubMed Google Scholar
• Yeldandi, A. V., Rao, M. S. & Reddy, J. K. Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis. Mutat. Res. 448, 159–177 (2000).
  Article CAS PubMed Google Scholar
• Rusyn, I., Rose, M. L., Bojes, H. K. & Thurman, R. G. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxid. Redox Signal. 2, 607–621 (2000).
  Article CAS PubMed Google Scholar
• Rusyn, I. et al. Phthalates rapidly increase production of reactive oxygen species in vivo: role of Kupffer cells. Mol. Pharmacol. 59, 744–750 (2001).
  Article CAS PubMed Google Scholar
• Ashby, J. et al. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13, S1–S117 (1994).
  Article PubMed Google Scholar
• Cattley, R. C. et al. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27, 47–60 (1998).
  Article CAS PubMed Google Scholar
• Bentley, P. et al. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31, 857–907 (1993).
  Article CAS PubMed Google Scholar
• Scotto, C., Keller, J. M., Schohn, H. & Dauca, M. Comparative effects of clofibrate on peroxisomal enzymes of human (Hep EBNA2) and rat (FaO) hepatoma cell lines. Eur. J. Cell Biol. 66, 375–381 (1995).
  CAS PubMed Google Scholar
• Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L. & Johnson, E. F. Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. 53, 14–22 (1998).
  Article CAS PubMed Google Scholar
• Tugwood, J. D., Aldridge, T. C., Lambe, K. G., Macdonald, N. & Woodyatt, N. J. Peroxisome proliferator-activated receptors: structures and function. Ann. NY Acad. Sci. 804, 252–265 (1996).
  Article CAS PubMed Google Scholar
• Maloney, E. K. & Waxman, D. J. _trans_-Activation of PPARα and PPARγ by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161, 209–218 (1999).
  Article CAS PubMed Google Scholar
• Woodyatt, N. J., Lambe, K. G., Myers, K. A., Tugwood, J. D. & Roberts, R. A. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20, 369–372 (1999).
  Article CAS PubMed Google Scholar
• Lambe, K. G., Woodyatt, N. J., Macdonald, N., Chevalier, S. & Roberts, R. A. Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol. Lett. 110, 119–127 (1999).
  Article CAS PubMed Google Scholar
• Lake, B. G., Phillips, J. C., Linnell, J. C. & Gangolli, S. D. The in vitro hydrolysis of some phthalate diesters by hepatic and intestinal preparations from various species. Toxicol. Appl. Pharmacol. 39, 239–248 (1977).
  Article CAS PubMed Google Scholar
• Rhodes, C. et al. Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl) phthalate (DEHP) in rats and marmosets: extrapolation of effects in rodents to man. Environ. Health Perspect. 65, 299–307 (1986).
  CAS PubMed PubMed Central Google Scholar
• Anderson, W. A., Castle, L., Scotter, M. J., Massey, R. C. & Springall, C. A biomarker approach to measuring human dietary exposure to certain phthalate diesters. Food Addit. Contam. 18, 1068–1074 (2001).
  Article CAS PubMed Google Scholar
• Sarraf, P. et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med. 4, 1046–1052 (1998).
  Article CAS PubMed Google Scholar
• Tanaka, T. et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61, 2424–2428 (2001).
  CAS PubMed Google Scholar
• Osawa, E. et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124, 361–367 (2003).
  Article CAS PubMed Google Scholar
• Saez, E. et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med. 4, 1058–1061 (1998).
  Article CAS PubMed Google Scholar
• Lefebvre, A. M. et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nature Med. 4, 1053–1057 (1998).
  Article CAS PubMed Google Scholar
• Wasan, H. S., Novelli, M., Bee, J. & Bodmer, W. F. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl Acad. Sci. USA 94, 3308–3313 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Girnun, G. D. et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl Acad. Sci. USA 99, 13771–13776 (2002). Paper that addresses the controversial role of Pparγ activation in colon carcinogenesis. The data presented indicate that the consequence of the activation of Pparγ on the development of colon tumours might depend on the existence of a previous mutation event in the Apc–β-catenin pathway.
  Article CAS PubMed PubMed Central Google Scholar
• Girnun, G. D. & Spiegelman, B. M. PPARγ ligands: taking Ppart in chemoprevention. Gastroenterology 124, 564–567 (2003).
  Article CAS PubMed Google Scholar
• Mueller, E. et al. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell 1, 465–470 (1998).
  Article CAS PubMed Google Scholar
• Elstner, E. et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl Acad. Sci. USA 95, 8806–8811 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Mehta, R. G., Williamson, E., Patel, M. K. & Koeffler, H. P. A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J. Natl Cancer Inst. 92, 418–423 (2000).
  Article CAS PubMed Google Scholar
• Suh, N. et al. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 59, 5671–5673 (1999).
  CAS PubMed Google Scholar
• Clay, C. E., Monjazeb, A., Thorburn, J., Chilton, F. H. & High, K. P. 15-Deoxy-δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J. Lipid Res. 43, 1818–1828 (2002).
  Article CAS PubMed Google Scholar
• Kubota, T. et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344–3352 (1998).
  CAS PubMed Google Scholar
• Mueller, E. et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl Acad. Sci. USA 97, 10990–10995 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Hisatake, J. I. et al. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res. 60, 5494–5498 (2000).
  CAS PubMed Google Scholar
• Aldred, M. A. et al. Peroxisome proliferator-activated receptor γ is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 22, 3412–3416 (2003).
  Article CAS PubMed Google Scholar
• Altiok, S., Xu, M. & Spiegelman, B. M. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11, 1987–1998 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Shao, D. & Lazar, M. A. Peroxisome proliferator activated receptor γ, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation. J. Biol. Chem. 272, 21473–21478 (1997).
  Article CAS PubMed Google Scholar
• Heaney, A. P., Fernando, M. & Melmed, S. PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111, 1381–1388 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Morrison, R. F. & Farmer, S. R. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J. Biol. Chem. 274, 17088–17097 (1999).
  Article CAS PubMed Google Scholar
• Clay, C. E., Atsumi, G. I., High, K. P. & Chilton, F. H. Early de novo gene expression is required for 15-deoxy-Δ 12,14-prostaglandin J2-induced apoptosis in breast cancer cells. J. Biol. Chem. 276, 47131–47135 (2001).
  Article CAS PubMed Google Scholar
• Kitamura, S. et al. PPARγ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in _ras_-transformed rat intestinal epithelial cells. Int. J. Cancer 94, 335–342 (2001).
  Article CAS PubMed Google Scholar
• Toyota, M. et al. Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci. 70, 1565–1575 (2002).
  Article CAS PubMed Google Scholar
• Qin, C. et al. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res. 63, 958–964 (2003).
  CAS PubMed Google Scholar
• Wang, C. et al. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol. Cell. Biol. 21, 3057–3070 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M. & DuBois, R. N. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J. Biol. Chem. 276, 29681–29687 (2001).
  Article CAS PubMed Google Scholar
• Gupta, R. A. et al. Peroxisome proliferator-activated receptor γ and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J. Biol. Chem. 278, 7431–7438 (2003).
  Article CAS PubMed Google Scholar
• Chen, G. G. et al. Apoptosis induced by activation of peroxisome-proliferator activated receptor-γ is associated with Bcl-2 and NF-κB in human colon cancer. Life Sci. 70, 2631–2646 (2002).
  Article CAS PubMed Google Scholar
• Satoh, T. et al. Activation of peroxisome proliferator-activated receptor-γ stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 21, 2171–2180 (2002).
  Article CAS PubMed Google Scholar
• Patel, L. et al. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr. Biol. 11, 764–768 (2001).
  Article CAS PubMed Google Scholar
• Farrow, B. & Evers, B. M. Activation of PPARγ increases PTEN expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 301, 50–53 (2003).
  Article CAS PubMed Google Scholar
• Xin, X., Yang, S., Kowalski, J. & Gerritsen, M. E. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 9116–9121 (1999).
  Article CAS PubMed Google Scholar
• Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl Acad. Sci. USA 94, 237–241 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Demetri, G. D. et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. USA 96, 3951–3956 (1999). Paper that describes the striking beneficial effects that are observed after PPARγ agonists are given to treat patients suffering from liposarcoma. These data indicate that troglitazone is a promising drug in the treatment of certain tumours.
  Article CAS PubMed PubMed Central Google Scholar
• Theocharis, S. et al. Expression of peroxisome proliferator activated receptor-γ in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36, 249–255 (2002).
  Article PubMed Google Scholar
• Gupta, R. A. & Dubois, R. N. Controversy: PPARγ as a target for treatment of colorectal cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G266–G269 (2002).
  Article CAS PubMed Google Scholar
• Dreyer, C. et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879–887 (1992).
  Article CAS PubMed Google Scholar
• Kliewer, S. A. et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 91, 7355–7359 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Amri, E. Z., Bonino, F., Ailhaud, G., Abumrad, N. A. & Grimaldi, P. A. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem. 270, 2367–2371 (1995).
  Article CAS PubMed Google Scholar
• Matsuo, H. & Strauss, J. F. 3rd. Peroxisome proliferators and retinoids affect JEG-3 choriocarcinoma cell function. Endocrinology 135, 1135–1145 (1994).
  Article CAS PubMed Google Scholar
• Jow, L. & Mukherjee, R. The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR α and thyroid hormone receptors. J. Biol. Chem. 270, 3836–3840 (1995).
  Article CAS PubMed Google Scholar
• He, T. C., Chan, T. A., Vogelstein, B. & Kinzler, K. W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345 (1999). Important report on the identification of PPARβ/δ as a potential target of the APC–β-catenin tumour-suppressor pathway. This paper also indicates that the activity COX2 in colon tumours might provide PPAR ligands.
  Article CAS PubMed PubMed Central Google Scholar
• Shao, J., Sheng, H. & DuBois, R. N. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 62, 3282–3288 (2002).
  CAS PubMed Google Scholar
• Gupta, R. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275–13280 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Park, B. H., Vogelstein, B. & Kinzler, K. W. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc. Natl Acad. Sci. USA 98, 2598–2603 (2001). Based on a model of grafts using PPARbβ/δ wild-type or null cells, this paper shows that PPARβ/δ activity can affect tumorigenesis and indicates that PPARβ/δ inhibitors could inhibit tumour growth.
  Article CAS PubMed PubMed Central Google Scholar
• Barak, Y. et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc. Natl Acad. Sci. USA 99, 303–308 (2002).
  Article CAS PubMed Google Scholar
• Jaeckel, E. C. et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127, 1253–1259 (2001).
  Article CAS PubMed Google Scholar
• Tong, B. J. et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-δ in human endometrial adenocarcinoma. Neoplasia 2, 483–490 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Suchanek, K. M., May, F. J., Lee, W. J., Holman, N. A. & Roberts-Thomson, S. J. Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int. J. Biochem. Cell Biol. 34, 1051–1058 (2002).
  Article CAS PubMed Google Scholar
• Michalik, L. et al. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol. 154, 799–814 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Tan, N. S. et al. Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15, 3263–3277 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Peters, J. M. et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20, 5119–5128 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Hao, C. M., Redha, R., Morrow, J. & Breyer, M. D. Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress. J. Biol. Chem. 277, 21341–21345 (2002).
  Article CAS PubMed Google Scholar
• Hatae, T., Wada, M., Yokoyama, C., Shimonishi, M. & Tanabe, T. Prostacyclin-dependent apoptosis mediated by PPAR δ. J. Biol. Chem. 276, 46260–46267 (2001).
  Article CAS PubMed Google Scholar
• Hellemans, K. et al. Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology 124, 184–201 (2003).
  Article CAS PubMed Google Scholar
• Zhang, J. et al. Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J. Biol. Chem. 277, 11505–11512 (2002).
  Article CAS PubMed Google Scholar
• Vosper, H. et al. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J. Biol. Chem. 276, 44258–44265 (2001).
  Article CAS PubMed Google Scholar
• Saluja, I., Granneman, J. G. & Skoff, R. P. PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 33, 191–204 (2001).
  Article CAS PubMed Google Scholar
• Dannenberg, A. J. & DuBois, R. N. COX–2. A new target for cancer prevention and treatment (Karger, New Brunswick, 2003).
  Google Scholar
• Purdue, P. E. & Lazarow, P. B. Peroxisome biogenesis. Annu. Rev. Cell Dev. Biol. 17, 701–752 (2001).
  Article CAS PubMed Google Scholar
• Kersten, S., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. Nature 405, 421–424 (2000).
  Article CAS PubMed Google Scholar
• Deeb, S. S. et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet. 20, 284–287 (1998).
  Article CAS PubMed Google Scholar
• Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W. & Kahn, C. R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953–959 (1998).
  Article CAS PubMed Google Scholar
• Barroso, I. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880–883 (1999).
  Article CAS PubMed Google Scholar
• Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M. & Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61, 6213–6218 (2001).
  CAS PubMed Google Scholar
• Baek, S. J., Wilson, L. C., Hsi, L. C. & Eling, T. E. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278, 5845–5853 (2003).
  Article CAS PubMed Google Scholar
• Sarraf, P. et al. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol. Cell 3, 799–804 (1999).
  Article CAS PubMed Google Scholar
• Kroll, T. G. et al. PAX8–PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289, 1357–1360 (2000).
  Article CAS PubMed Google Scholar
• Marques, A. R. et al. Expression of PAX8–PPAR γ1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87, 3947–3952 (2002).
  CAS PubMed Google Scholar
• Nikiforova, M. N. et al. RAS point mutations and PAX8–PPAR γ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318–2326 (2003).
  Article CAS PubMed Google Scholar
• Cheung, L. et al. Detection of the PAX8–PPAR γ fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 88, 354–357 (2003).
  Article CAS PubMed Google Scholar
• Ikezoe, T. et al. Mutational analysis of the peroxisome proliferator-activated receptor γ gene in human malignancies. Cancer Res. 61, 5307–5310 (2001).
  CAS PubMed Google Scholar
• Brockman, J. A., Gupta, R. A. & Dubois, R. N. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115, 1049–1055 (1998).
  Article CAS PubMed Google Scholar
• Asou, H. et al. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor γ, and retinoids. Int. J. Oncol. 15, 1027–1031 (1999).
  CAS PubMed Google Scholar
• Han, S. W., Greene, M. E., Pitts, J., Wada, R. K. & Sidell, N. Novel expression and function of peroxisome proliferator-activated receptor γ (PPARγ) in human neuroblastoma cells. Clin. Cancer Res. 7, 98–104 (2001).
  CAS PubMed Google Scholar
• Koga, H. et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33, 1087–1097 (2001).
  Article CAS PubMed Google Scholar
• Wakino, S. et al. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. J. Biol. Chem. 275, 22435–22441 (2000).
  Article CAS PubMed Google Scholar
• Takahashi, N. et al. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 455, 135–139 (1999).
  Article CAS PubMed Google Scholar
• Ohta, K., Endo, T., Haraguchi, K., Hershman, J. M. & Onaya, T. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 86, 2170–2177 (2001).
  CAS PubMed Google Scholar
• Houston, K. D. et al. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor γ ligands in uterine leiomyoma. Cancer Res. 63, 1221–1227 (2003).
  CAS PubMed Google Scholar
• Roth, A. D. et al. PPAR γ activators induce growth arrest and process extension in B12 oligodendrocyte-like cells and terminal differentiation of cultured oligodendrocytes. J. Neurosci. Res. 72, 425–435 (2003).
  Article CAS PubMed Google Scholar
• Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A. & Evans, R. M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241–252 (1998).
  Article CAS PubMed Google Scholar
• Chang, T. H. & Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res. 60, 1129–1138 (2000).
  CAS PubMed Google Scholar
• Yang, W. L. & Frucht, H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22, 1379–1383 (2001).
  Article CAS PubMed Google Scholar
• Chinetti, G. et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573–25580 (1998).
  Article CAS PubMed Google Scholar
• Padilla, J., Kaur, K., Cao, H. J., Smith, T. J. & Phipps, R. P. Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J. Immunol. 165, 6941–6948 (2000).
  Article CAS PubMed Google Scholar
• Toyoda, M. et al. A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50, 563–567 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Keelan, J. A. et al. 15-Deoxy-Δ(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochem. Biophys. Res. Commun. 262, 579–585 (1999).
  Article CAS PubMed Google Scholar
• Okuno, A. et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354–1361 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Herbert, B. S. et al. A peroxisome proliferator-activated receptor-γ agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells. Cancer Res. 63, 1914–1919 (2003).
  CAS PubMed Google Scholar